# US 2020/0347070 A1 · Heterocyclic compound, preparation method and use thereof in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347070 A1
- Document ID: US20200347070A1
- Status: Published application
- Kind: A1
- Application number: 16/963,020
- Filed: 2019-01-18
- Published: 2020-11-05
- Earliest claimed: 2018-01-19
- Assignees: Suzhou Sinovent Pharmaceuticals Co., Ltd.
- Applicants: Suzhou Sinovent Pharmaceuticals Co., Ltd.
- Inventors: Yuchuan Wu; Xi Chen; Shaoqiang Huang; Yonghan Hu; Linhai Qu; Jinlian Zhu; Xiao Liu
- Web page: https://patentgrep.com/patent/US20200347070A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D 487/04: Ortho-condensed systems
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.

## Claims

### Claim 1

A compound of formula (I) and/or formula (II), or a tautomer thereof or a pharmaceutically acceptable salt thereof:
wherein, ring A is a six-membered aromatic or heteroaromatic ring and ring B is a five-membered heteroaromatic ring,
W1 is selected from N and O;
W2 is selected from CR6 and NR7;
W3 and W4 are each independently selected from C and N;
W5, W6 and W7 are each independently selected from CR8 and N;
R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl;
provided that the following are excluded:
when W1 is selected from O, W3, —W4, —W5, —W6, and W7 are CR6; W2, when W1 and W4 are selected from N, W2 is CR6, W3 is C, and W5, W6, and W7 are CR8.

### Claim 2 (depends on 1)

The compound of formula (Ia) and/or formula (IIa) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1:
wherein,
W2 is selected from CR6;
W5, W6 and W7 are each independently selected from CR8 and N;
R1, R2, R3, R4, R5, R6, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 3 (depends on 2)

The compound of formula (Ib) and/or (IIb) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 2:
wherein,
W5 and W7 are each independently selected from CR8 or N;
R1, R2, R3, R4, R5, R6, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 4 (depends on 2)

The compound of formula (Ic) and/or formula (IIc) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 2:
wherein,
W6 and W7 are each independently selected from CR6 or N;
R1, R2, R3, R4, R5, R6, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 5 (depends on 2)

The compound of formula (Id) and/or formula (II d) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 2:
wherein,
W7 is selected from CR8 or N;
R1, R2, R3, R4, R5, R6, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 6 (depends on 1)

The compound of formula (Ie) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1:
wherein,
W5, W6 and W7 are each independently selected from CR8 and N;
R1, R2, R3, R4, R5, R7, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 7 (depends on 1)

The compound of formula (If) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1:
wherein,
W2 is selected from CR6;
W5, W6 and W7 are each independently selected from CR8 and N;
R1, R2, R3, R4, R5, R6, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 8 (depends on 1)

The compound of formula (Ig) or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1:
wherein,
W2 is selected from CR6;
W5, W6 and W7 are each independently selected from CR8 and N;
R1, R2, R3, R4, R5, R6, and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxy, C1-20 alkyl, C1-20 alkoxy, and C1-20 haloalkyl.

### Claim 9 (depends on 1)

The compound or the tautomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 selected from the group consisting of:
(3,5-dibromo-4-hydroxyphenyl)(2-ethylimidazo[1,2-c]pyrimidin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethylfuro[3,2-c]pyridin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-7-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl)methanone;
(6-bromo-2-ethylimidazo[1,2-a]pyrimidin-3-yl)(3,5-dibromo-4-hydroxyphenyl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl)methanone;
(6-chloro-2-ethylimidazo[1,2-a]pyrimidin-3-yl)(3,5-dibromo-4-hydroxyphenyl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-7-(trifluoromethyl)imidazo[1,2-c]pyrimidin-3-yl)methanone;
(4,6-dibromo-5-hydroxypyridin-2-yl)(2-ethyl-5-fluoro-2H-indazol-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-5-fluoro-2H-indazol-3-yl)methanone;
3-bromo-5-(2-ethyl-6-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-carbonyl)-2-hydroxybenzonitrile;
3-bromo-5-(2-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-3-carbonyl)-2-hydroxybenzonitrile;
3-bromo-5-(3-ethyl-6-(trifluoromethyl)imidazo[1,2-a]pyrimidin-2-carbonyl)-2-hydroxybenzonitrile;
5-(2-ethyl-6-fluoroimidazo[1,2-a]pyrimidine-3-carbonyl)-2-hydroxyisophthalonitrile 2,2,2-trifluoroacetate;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-2H-pyrazolo[4,3-c]pyridin-3-yl)methanone;
3-bromo-5-(2-ethyl-7-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-carbonyl)-2-hydroxybenzonitrile;
(3-bromo-4-hydroxy-5-(trifluoromethyl)phenyl)(2-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-3-yl)methanone;
(3-bromo-4-hydroxy-5-(trifluoromethyl)phenyl)(2-ethyl-6-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(3-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-2-yl)methanone;
3-bromo-5-(3-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-2-carbonyl)-2-hydroxybenzonitrile;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-7-(2H)imidazo[1,2-c]pyrimidin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-2H-indazol-3-yl)methanone;
(4,6-dibromo-5-hydroxypyridin-2-yl)(2-ethyl-5-fluoro-benzofuran-3-yl)methanone;
(4-bromo-5-hydroxy-6-(trifluoromethyl)pyridin-2-yl)(2-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-3-yl)methanone;
(4-bromo-5-hydroxy-6-(trifluoromethyl)pyridin-2-yl)(2-ethyl-6-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl)methanone;
(7-ethylimidazo[1,2-a][1,3,5]triazin-6-yl)(3,5-dibromo-4-hydroxphenyl)methanone;
(7-hydroxy-2-ethylimidazo[1,2-f]pyrimidin-3-yl)(3,5-dibromo-4-hydroxyphenyl)methanone;
(3-bromo-4-hydroxy-5-(trifluoromethyl)phenyl)(3-ethyl-6-fluoroimidazo[1,2-a]pyrimidin-2-yl)methanone;
(3-bromo-4-hydroxy-5-(trifluoromethyl)phenyl)(3-ethyl-6-(trifluoromethyl)-imidazo[1,2-a]pyrimidin-2-yl)methanone;
(2,6-difluoro-3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-fluoro-imidazo[1,2-a]pyrimidin-3-yl)methanone;
(2,6-difluoro-3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-2H-pyrazolo[3,4-d]pyrimidin-3-yl)methanone;
3-bromo-5-(2-ethyl-2H-pyrazolo[3,4-d]pyrimidine-3-carbonyl)-2-hydroxybenzonitrile;
(3,5-dibromo-4-hydroxyphenyl)(2-ethylimidazo[4,5-c]pyrimidin-3-yl)methanone;
(3,5-dibromo-4-hydroxyphenyl)(2-ethylfuro[3,2-c]pyridin-3-yl)methanone;
2,6-dibromo-4-([2-ethylimidazo[1,2-a]pyrimidin-3-yl]carbonyl)phenol;
(7-chloro-2-ethylimidazo[1,2-f]pyrimidin-3-yl)(3,5-dibromo-4-hydroxphenyl)methanone;
3-bromo-5-(2-ethylimidazo[1,2-a]pyrimidine-3-carbonyl)-2-hydroxybenzonitrile;
(4-bromo-5-hydroxy-6-(trifluoromethyl)pyridin-2-yl)(2-ethylimidazo[1,2-a]pyrimidin-3-yl)methanone; and
(3-bromo-4-hydroxy-5-(trifluoromethyl)phenyl)(2-ethylimidazo[1,2-a]pyrimidin-3-yl)methanone;
or tautomers or pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 1)

The preparation method of the compound of formula (Ia) and/or formula (Ib) according to claim 1, comprising the steps of:
Step 1: a heteroaromatic amine compound 1 and a 1,3-diketone compound 2 undergo cyclization to give anisole intermediate compound 3;
Step 2: the anisole intermediate compound 3 obtained in Step 1 undergoes demethylation to give a phenol compound 4 in the presence of a catalyst;
Step 3: the phenol compound 4 obtained in Step 2 undergoes halogenation to give phenol compound 5, wherein X represents halogen,
and W5, W6, W7, R1, R2, and R6 are as defined in claim 1.

### Claim 11 (depends on 10)

The preparation method of the compound of formula (Ia) and/or formula (Ib) according to claim 10, further comprising:
Step 4: the phenol compound 5 obtained in Step 3 further undergoes cyanation in which one or more halogens on the phenol ring are substituted with cyano.

### Claim 12 (depends on 1)

The preparation method of the compound of formula (Ia) and/or formula (Ib) according to claim 1, comprising the steps of:
Step 1: the compound 6 and a acyl halide compound 7 react under an alkaline condition to give an anisole intermediate compound 8;
Step 2: the anisole intermediate compound 8 obtained in Step 1 undergoes demethylation to give a phenol compound 9 in the presence of a catalyst;
Step 3: the phenol compound 9 obtained in Step 2 undergoes halogenation to give a phenol compound 10, wherein X represents halogen,
and W5, W6, W7, R1, R2, and R7 are as defined in claim 1.

### Claim 13 (depends on 10)

The preparation method of the compound of formula (Ia) and/or formula (Ib) according to claim 10, further comprising:
Step 4: the phenol compound 5 obtained in Step 3 further undergoes cyanation in which one or more halogens on the phenol ring are substituted with cyano.

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising the compound according to claim 1 or the tautomer thereof or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1, 14)

Use of the compound of claim 1 or the pharmaceutical composition of claim 14 in preparing a therapeutic for preventing and/or treating hyperuricemia and gout.
